Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01344993 |
Recruitment Status :
Completed
First Posted : April 29, 2011
Last Update Posted : July 7, 2021
|
Sponsor:
Astellas Institute for Regenerative Medicine
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | August 19, 2015 |
Actual Study Completion Date : | August 19, 2015 |
Certification/Extension First Submitted : | August 17, 2016 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):